Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1 2Phase 2 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 1Gynecologic 1CNS 1

Conditions

Ovarian High Grade Serous Adenocarcinoma 1Medulloblastoma 1Locally Advanced Non-Small Cell Lung Cancer 1Leukemia, Myeloid, Acute 1Hypoxia 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Atovaquone × Clear all
NCT04648033 2026-01-29

ARCADIAN

University of Oxford

Phase 1 Completed
21 enrolled 21 charts
Thoracic

Locally Advanced Non-Small Cell Lung Cancer

NCT03568994 2026-01-27

ATACC AML

Baylor College of Medicine

Phase EARLY_PHASE1 Completed
26 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05998135 2025-09-11

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Emory University

Phase 2 Recruiting
28 enrolled
Gynecologic

Ovarian High Grade Serous Adenocarcinoma

NCT06624371 2025-07-22

AflacBT2303

Emory University

Phase 1 Recruiting
18 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

NCT02628080 2019-09-04

ATOM

University of Oxford

Phase EARLY_PHASE1 Completed
46 enrolled
Thoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡